Multicenter phase II study of irinotecan plus weekly bolus 5-FU and high dose l-leucovorin for patients with metastatic colorectal cancer (OGSG 0201).

被引：0
|
作者：
Ishida, H [1 ]
Mishima, H [1 ]
Iwamoto, S [1 ]
Morimoto, T [1 ]
Kato, T [1 ]
Tsujinaka, T [1 ]
Furukawa, Y [1 ]
机构：
[1] Osaka Gastrointestinal Ctr, Chemotherapy Study Grp, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3718
引用
收藏
页码：298S / 298S
页数：1
相关论文
共 50 条
  • [21] Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer
    Leonard, P
    Seymour, MT
    James, R
    Hochhauser, D
    Ledermann, JA
    BRITISH JOURNAL OF CANCER, 2002, 87 (11) : 1216 - 1220
  • [22] Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer
    P Leonard
    M T Seymour
    R James
    D Hochhauser
    J A Ledermann
    British Journal of Cancer, 2002, 87 : 1216 - 1220
  • [23] A phase II study of weekly oxaliplatin and high dose 5-FU with LCV as second line therapy in patients with advanced colorectal cancer
    Janinis, J
    Fountzilas, G
    Papakostas, P
    Efstathiou, E
    Valagouti, D
    Skarlos, D
    ANNALS OF ONCOLOGY, 1998, 9 : 44 - 44
  • [24] Phase II trial evaluating a 2 weekly regimen of irinotecan (IR) and 5-FU/leucovorin (LV) in patients with metastatic pancreatic cancer refractory to chemotherapy.
    Ng, M
    Norman, AR
    Cunningham, D
    Waters, J
    Oates, J
    Ross, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 370S - 370S
  • [25] Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan (vol 43, pg 842, 2008)
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Shouji, Daigo
    Shinozaki, Eiji
    Matsusaka, Satoshi
    Chin, Keisho
    Oya, Masatoshi
    Yamaguchi, Toshiharu
    Muto, Tetsuichiro
    Hatake, Kiyohiko
    JOURNAL OF GASTROENTEROLOGY, 2009, 44 (07) : 801 - 801
  • [26] Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).
    Kopetz, S.
    Abbruzzese, J. L.
    Eng, C.
    Adinin, R. B.
    Morris, J.
    Wolff, R. A.
    Lin, E.
    Chang, D. Z.
    Hoff, P.
    Bogaard, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 165S - 165S
  • [27] 5-fluorouracil plus calcium leucovorin and irinotecan in the treatment of metastatic colorectal cancer: Phase II study
    Salek, T.
    Mego, M.
    Mardiak, J.
    Porsok, S.
    Hlavata, Z.
    Dolinsky, J.
    Palacka, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 86 - 86
  • [28] Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan
    Tai, CJ
    Liu, JH
    Chen, WS
    Lin, JK
    Wang, WS
    Yen, CC
    Chiou, TJ
    Chen, PM
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (03) : 136 - 140
  • [29] Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU):: A phase II study
    Antón, A
    Aranda, E
    Carrato, A
    Marcuello, E
    Massutti, B
    Cervantes, A
    Abad, A
    Sastre, J
    Fenández-Martos, C
    Gallén, M
    Díaz-Rubio, E
    Huarte, L
    Balcells, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (08): : 639 - 643
  • [30] A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer
    Rosati, G
    Rossi, A
    Reggiardo, G
    Manzione, L
    ONCOLOGY, 2002, 62 (03) : 209 - 215
12345